NPM1 and acute myeloid leukemia: In fact, TP53 alterations may co-exist with some other frequent AML-related single-nucleotide mutations such as TET2, NPM1, FLT3, DNMT3A, IDH1, and IDH2; in addition, TP53-mutant AML are often characterized by recurrent co-occurring karyotypic structural aberrations, especially genomic abnormalities detected in certain chromosomes (chromosome 5, 7, and 17), and with events involving chromothripsis (36–38).